Please login to the form below

Not currently logged in

Ronald Berenson to lead Aequus BioPharma

Joins the Cell Therapeutics subsidiary as president and CEO

Cell Therapeutics' US subsidiary Aequus BioPharma has appointed Ronald Berenson as president and CEO.

In his new role he will be tasked with expanding Washington State-based Aequus' GlycoPolymer technology, which aims to create novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current treatments.

Berenson said: "There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and compliance continue to be issues with therapeutic proteins due to the need for frequent injections.

"I believe that Aequus's novel approach could address these challenges with the potential to be applied to a wide spectrum of therapeutics."

Berenson, who was most recently an Entrepreneur in Residence at the University of Washington, has spent more than 20 years in senior biotech management roles.

During this time he co-founded HemaQuest Pharmaceuticals, serving as president and CEO for its first three years, and founded the oncology-focused biotech companies Xcyte Therapies and CellPro.

11th December 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...